BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld Asia
Home
» Regulatory actions for June 30-July 6, 2020
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Regulatory actions for June 30-July 6, 2020
July 7, 2020
No Comments
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Alterity, Astrazeneca, Beigene, Biophytis, Daiichi Sankyo, Eusa, Gilead Sciences, Golden, Hangzhou Yuyuan, Medicinova, Merck, Mesoblast, Mezzion, Mylan, Nuvox, Obseva, Prestige, Revive, Sinovac, TC Biopharm.
BioWorld Asia
Briefs
Regulatory actions